ArticleAlzheimer's & dementia (New York, N. Y.)2020
Evaluating the Alzheimer's disease data landscape.
Article in Alzheimer's & dementia (New York, N. Y.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed.
- Multimodal neuroimaging and AI integration in cognitive disorders: advances, challenges, and future directions for precision medicine.Psychoradiology · 2026Review
- A new ANMerge-based blood transcriptomic resource to support Alzheimer's disease research.medRxiv : the preprint server for health sciences · 2025Article
- The Alzheimer's Disease Neuroimaging Initiative-4 (ADNI-4) Engagement Core: A culturally informed, community-engaged research (CI-CER) model to advance brain health equity.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Review
- A Protocol for the Inclusion of Minoritized Persons in Alzheimer Disease Research From the ADNI3 Diversity Taskforce.JAMA network open · 2024Observational
- Meeting report of the fifth annual workshop on Principles and Techniques for Improving Preclinical to Clinical Translation in Alzheimer's Disease Research.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Irregular word reading as a marker of semantic decline in Alzheimer's disease: implications for premorbid intellectual ability measurement.Alzheimer's research & therapy · 2024Article
- Semantic Harmonization of Alzheimer's Disease Datasets Using AD-Mapper.Journal of Alzheimer's disease : JAD · 2024Article
- Participant completion of longitudinal assessments in an online cognitive aging registry: The role of medical conditions.Alzheimer's & dementia (New York, N. Y.) · 2024Article
- Data-Driven Thresholding Statistically Biases ATN Profiling across Cohort Datasets.The journal of prevention of Alzheimer's disease · 2024Article
- A Comparison of an Australian Observational Longitudinal Alzheimer's Disease Cohort to Community-Based Australian Data.Journal of Alzheimer's disease : JAD · 2024Observational
- Deep learning-based patient stratification for prognostic enrichment of clinical dementia trials.Brain communications · 2024Article
- Design and feasibility of an Alzheimer's disease blood test study in a diverse community-based population.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023Article
- Alzheimer Disease Biomarkers: Moving from CSF to Plasma for Reliable Detection of Amyloid and tau Pathology.Clinical chemistry · 2023Article
- Brain health registry updates: An online longitudinal neuroscience platform.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023Article
- Irregular word reading as a marker of cognitive and semantic decline in Alzheimer's disease rather than an estimate of premorbid intellectual abilities.Research square · 2023Article
- Digital culturally tailored marketing for enrolling Latino participants in a web-based registry: Baseline metrics from the Brain Health Registry.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023Article
- Improving generalizability and study design of Alzheimer's disease cohort studies in the United States by including under-represented populations.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023Article
- Should artificial intelligence be used in conjunction with Neuroimaging in the diagnosis of Alzheimer's disease?Frontiers in aging neuroscience · 2023Review
- The Community Engaged Digital Alzheimer's Research (CEDAR) Study: A Digital Intervention to Increase Research Participation of Black American Participants in the Brain Health Registry.The journal of prevention of Alzheimer's disease · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
introductionNumerous studies have collected Alzheimer's disease (AD) cohort data sets. To achieve reproducible, robust results in data-driven approaches, an evaluation of the present data landscape is vital.
methodsPrevious efforts relied exclusively on metadata and literature. Here, we evaluate the data landscape by directly investigating nine patient-level data sets generated in major clinical cohort studies.
resultsThe investigated cohorts differ in key characteristics, such as demographics and distributions of AD biomarkers. Analyzing the ethnoracial diversity revealed a strong bias toward White/Caucasian individuals. We described and compared the measured data modalities. Finally, the available longitudinal data for important AD biomarkers was evaluated. All results are explorable through our web application ADataViewer (https://adata.scai.fraunhofer.de). DISCUSSION: Our evaluation exposed critical limitations in the AD data landscape that impede comparative approaches across multiple data sets. Comparison of our results to those gained by metadata-based approaches highlights that thorough investigation of real patient-level data is imperative to assess a data landscape.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.